clinical trial · NCT04354246
COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies
Advanced CancerOvarian CancerLung CancerColon CancerPlasma Cell NeoplasmMultiple MyelomaHNSCCMicrosatellite Stable Colorectal CarcinomaDose escalation: COM902 monotherapy.Evaluation of safety/tolerability: COM902 in combination with COM701 (both at the RDFE)Cohort expansion: COM902 (RDFE) monotherapy.Cohort expansion: COM902 in combination with COM701 (both at the RDFE).Cohort expansion: Triplet combination of COM902 + COM701 + Pembrolizumab.
brief summary
Phase 1 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary antitumor activity of COM902 as monotherapy and in combination with COM701 in subjects with advanced malignancies.
started
Mar 31, 2020
primary completion
Dec 30, 2025
completion
Dec 30, 2025
last updated
May 22, 2025
official title
A Phase 1 Study of The Safety and Tolerability of COM902 in Subjects With Advanced Malignancies
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol